Article
Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.
Pharmacogenomics - 1 May 2016
Lopez-Lopez Elixabet, Gutierrez-Camino Angela, Astigarraga Itziar, Navajas Aurora, Echebarria-Barona Aizpea, Garcia-Miguel Purificacion, Garcia de Andoin Nagore, Lobo Carmen, Guerra-Merino Isabel, Martin-Guerrero Idoia, Garcia-Orad Africa
Abstract excerpt
AIM: Vincristine is an important component of acute lymphoblastic leukemia (ALL) treatment protocols that can cause neurotoxicity. Patients treated with LAL/SHOP protocols often suffer from vincristine-related neurotoxicity in early phases of treatment. Recently, a genome-wide association study connected a SNP in CEP72, involved in vincristine pharmacodynamics, with neurotoxicity during later phases of therapy,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
